Robert Henderson Nichols, DO | |
6225 N State Highway 161 Ste 200, Irving, TX 75038-2241 | |
(214) 687-0001 | |
Not Available |
Full Name | Robert Henderson Nichols |
---|---|
Gender | Male |
Speciality | Anesthesiology |
Experience | 11 Years |
Location | 6225 N State Highway 161 Ste 200, Irving, Texas |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1679910574 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207L00000X | Anesthesiology | BP10047100 (Texas) | Secondary |
207L00000X | Anesthesiology | R3389 (Texas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Baylor Scott & White All Saints Medical Center Fort Worth | Fort worth, TX | Hospital |
Baylor Scott & White Heart & Vascular Hospital - Dallas | Dallas, TX | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Northstar Anesthesia Iii Pa | 0042630501 | 335 |
Northstar Anesthesia Pa | 7315907128 | 290 |
News Archive
A highly advanced 10MP diagnostic imaging display capable of showing two 5MP images for back-to-back chest wall reads has been launched by medical technology leader NDS Surgical Imaging (NDSsi). The new 30-inch widescreen Dome S10 supports 10-bit and 8-bit grayscale image data through industry standard interfaces, eliminating the need for proprietary libraries. Featuring non-reflective glass for higher-clarity viewing, and state-of-the-art 4096 x 2560 resolution, the S10 has raised the bar in optical performance in mammography screening.
Athera Biotechnologies AB today announced that future development costs of its fully human antibody PC-mAb up until proof-of-concept will be co-funded by the European Union's Seventh Framework Programme for Research (FP7) through a collaborative research grant. Karolinska Development AB owns 65% of Athera Biotechnologies AB.
Boston Scientific Corporation today welcomed one-year data from the SPIRIT IV clinical trial comparing the XIENCE V((R)) (PROMUS((R))) Everolimus-Eluting Coronary Stent System to the TAXUS((R)) Express2(TM) Paclitaxel-Eluting Coronary Stent System. The results support the benefits of paclitaxel-eluting stents in diabetic patients. The trial enrolled 3,690 patients, including 1,140 diabetics, the largest diabetic subset ever studied in a drug-eluting stent clinical trial.
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
› Verified 1 days ago
Entity Name | Utmb Faculty Group Practice |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1942241146 PECOS PAC ID: 3375456734 Enrollment ID: O20031112000438 |
News Archive
A highly advanced 10MP diagnostic imaging display capable of showing two 5MP images for back-to-back chest wall reads has been launched by medical technology leader NDS Surgical Imaging (NDSsi). The new 30-inch widescreen Dome S10 supports 10-bit and 8-bit grayscale image data through industry standard interfaces, eliminating the need for proprietary libraries. Featuring non-reflective glass for higher-clarity viewing, and state-of-the-art 4096 x 2560 resolution, the S10 has raised the bar in optical performance in mammography screening.
Athera Biotechnologies AB today announced that future development costs of its fully human antibody PC-mAb up until proof-of-concept will be co-funded by the European Union's Seventh Framework Programme for Research (FP7) through a collaborative research grant. Karolinska Development AB owns 65% of Athera Biotechnologies AB.
Boston Scientific Corporation today welcomed one-year data from the SPIRIT IV clinical trial comparing the XIENCE V((R)) (PROMUS((R))) Everolimus-Eluting Coronary Stent System to the TAXUS((R)) Express2(TM) Paclitaxel-Eluting Coronary Stent System. The results support the benefits of paclitaxel-eluting stents in diabetic patients. The trial enrolled 3,690 patients, including 1,140 diabetics, the largest diabetic subset ever studied in a drug-eluting stent clinical trial.
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
› Verified 1 days ago
Entity Name | Northstar Anesthesia Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1912978610 PECOS PAC ID: 7315907128 Enrollment ID: O20041015000685 |
News Archive
A highly advanced 10MP diagnostic imaging display capable of showing two 5MP images for back-to-back chest wall reads has been launched by medical technology leader NDS Surgical Imaging (NDSsi). The new 30-inch widescreen Dome S10 supports 10-bit and 8-bit grayscale image data through industry standard interfaces, eliminating the need for proprietary libraries. Featuring non-reflective glass for higher-clarity viewing, and state-of-the-art 4096 x 2560 resolution, the S10 has raised the bar in optical performance in mammography screening.
Athera Biotechnologies AB today announced that future development costs of its fully human antibody PC-mAb up until proof-of-concept will be co-funded by the European Union's Seventh Framework Programme for Research (FP7) through a collaborative research grant. Karolinska Development AB owns 65% of Athera Biotechnologies AB.
Boston Scientific Corporation today welcomed one-year data from the SPIRIT IV clinical trial comparing the XIENCE V((R)) (PROMUS((R))) Everolimus-Eluting Coronary Stent System to the TAXUS((R)) Express2(TM) Paclitaxel-Eluting Coronary Stent System. The results support the benefits of paclitaxel-eluting stents in diabetic patients. The trial enrolled 3,690 patients, including 1,140 diabetics, the largest diabetic subset ever studied in a drug-eluting stent clinical trial.
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
› Verified 1 days ago
Entity Name | Northstar Anesthesia Ii Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1477066405 PECOS PAC ID: 2365701737 Enrollment ID: O20180110000102 |
News Archive
A highly advanced 10MP diagnostic imaging display capable of showing two 5MP images for back-to-back chest wall reads has been launched by medical technology leader NDS Surgical Imaging (NDSsi). The new 30-inch widescreen Dome S10 supports 10-bit and 8-bit grayscale image data through industry standard interfaces, eliminating the need for proprietary libraries. Featuring non-reflective glass for higher-clarity viewing, and state-of-the-art 4096 x 2560 resolution, the S10 has raised the bar in optical performance in mammography screening.
Athera Biotechnologies AB today announced that future development costs of its fully human antibody PC-mAb up until proof-of-concept will be co-funded by the European Union's Seventh Framework Programme for Research (FP7) through a collaborative research grant. Karolinska Development AB owns 65% of Athera Biotechnologies AB.
Boston Scientific Corporation today welcomed one-year data from the SPIRIT IV clinical trial comparing the XIENCE V((R)) (PROMUS((R))) Everolimus-Eluting Coronary Stent System to the TAXUS((R)) Express2(TM) Paclitaxel-Eluting Coronary Stent System. The results support the benefits of paclitaxel-eluting stents in diabetic patients. The trial enrolled 3,690 patients, including 1,140 diabetics, the largest diabetic subset ever studied in a drug-eluting stent clinical trial.
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
› Verified 1 days ago
Entity Name | Northstar Anesthesia Iii Pa |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1356968952 PECOS PAC ID: 0042630501 Enrollment ID: O20201022000080 |
News Archive
A highly advanced 10MP diagnostic imaging display capable of showing two 5MP images for back-to-back chest wall reads has been launched by medical technology leader NDS Surgical Imaging (NDSsi). The new 30-inch widescreen Dome S10 supports 10-bit and 8-bit grayscale image data through industry standard interfaces, eliminating the need for proprietary libraries. Featuring non-reflective glass for higher-clarity viewing, and state-of-the-art 4096 x 2560 resolution, the S10 has raised the bar in optical performance in mammography screening.
Athera Biotechnologies AB today announced that future development costs of its fully human antibody PC-mAb up until proof-of-concept will be co-funded by the European Union's Seventh Framework Programme for Research (FP7) through a collaborative research grant. Karolinska Development AB owns 65% of Athera Biotechnologies AB.
Boston Scientific Corporation today welcomed one-year data from the SPIRIT IV clinical trial comparing the XIENCE V((R)) (PROMUS((R))) Everolimus-Eluting Coronary Stent System to the TAXUS((R)) Express2(TM) Paclitaxel-Eluting Coronary Stent System. The results support the benefits of paclitaxel-eluting stents in diabetic patients. The trial enrolled 3,690 patients, including 1,140 diabetics, the largest diabetic subset ever studied in a drug-eluting stent clinical trial.
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
› Verified 1 days ago
Mailing Address | Practice Location Address |
---|---|
Robert Henderson Nichols, DO 1940 Berkeley Pl, Fort Worth, TX 76110-1209 Ph: (817) 307-9633 | Robert Henderson Nichols, DO 6225 N State Highway 161 Ste 200, Irving, TX 75038-2241 Ph: (214) 687-0001 |
News Archive
A highly advanced 10MP diagnostic imaging display capable of showing two 5MP images for back-to-back chest wall reads has been launched by medical technology leader NDS Surgical Imaging (NDSsi). The new 30-inch widescreen Dome S10 supports 10-bit and 8-bit grayscale image data through industry standard interfaces, eliminating the need for proprietary libraries. Featuring non-reflective glass for higher-clarity viewing, and state-of-the-art 4096 x 2560 resolution, the S10 has raised the bar in optical performance in mammography screening.
Athera Biotechnologies AB today announced that future development costs of its fully human antibody PC-mAb up until proof-of-concept will be co-funded by the European Union's Seventh Framework Programme for Research (FP7) through a collaborative research grant. Karolinska Development AB owns 65% of Athera Biotechnologies AB.
Boston Scientific Corporation today welcomed one-year data from the SPIRIT IV clinical trial comparing the XIENCE V((R)) (PROMUS((R))) Everolimus-Eluting Coronary Stent System to the TAXUS((R)) Express2(TM) Paclitaxel-Eluting Coronary Stent System. The results support the benefits of paclitaxel-eluting stents in diabetic patients. The trial enrolled 3,690 patients, including 1,140 diabetics, the largest diabetic subset ever studied in a drug-eluting stent clinical trial.
ProUroCare Medical, Inc. today announced the completion of a National Institute of Health and National Cancer Institute-supported clinical study. The study's purpose was to evaluate the ability of the company's ProUroScan imaging system to visualize and document abnormalities in the prostate detected or monitored by the digital rectal exam (DRE).
› Verified 1 days ago
Leonard D Morgan, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5605 N Macarthur Blvd, Suite 220, Irving, TX 75038 Phone: 972-714-0007 Fax: 972-714-0009 | |
Dr. Teddrick Lovell Dunson, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4301 N Macarthur Blvd Ste 107, Irving, TX 75038 Phone: 469-351-3432 Fax: 469-333-8025 | |
Jonathan Keewing Kwan, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4301 N Macarthur Blvd, Suite 101 (972) 255-5588, Irving, TX 75038 Phone: 972-855-5588 | |
Robert Groysman, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 220 O Connor Ridge Blvd Ste 105, Irving, TX 75038 Phone: 214-560-0000 Fax: 214-560-2555 | |
Philip O Smith, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 8041 N Macarthur Blvd Apt 2177, Irving, TX 75063 Phone: 214-405-8930 | |
Heather M. Gano, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 5605 N Macarthur Blvd, Suite #220, Irving, TX 75038 Phone: 972-714-0007 | |
Raphael Ye, DO Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 4441 W Airport Fwy Ste 215, Irving, TX 75062 Phone: 469-444-7246 |